This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Today's Health Winners and Losers

Shares of BioMarin Pharmaceutical (BMRN - Get Report) were among the best-performing health-related stocks Thursday, jumping 15% after the company said its treatment for phenylketonuria, an enzyme deficiency, performed well in a phase III trial.

BioMarin and its partner, Serono (SRA), said Phenoptin met its primary and secondary endpoints, demonstrating a statistically significant reduction at six weeks in blood phenylalanine levels when compared to a placebo. BioMarin and Serono plan to file marketing applications for Phenoptin for PKU in the U.S. and European Union in 2007.

Separately, BioMarin agreed to license its Orapred product line to privately held Alliant Pharmaceuticals. The license gives Alliant the exclusive right to market the pediatric asthma drug in North America. BioMarin will receive payments and royalties that are tied to the product's approval, launch and sales. BioMarin, which will retain the commercial rights to Orapred outside of North America, expects to launch Orapred ODT during the second half of 2006. Shares were trading up $1.84 to $14.29.

Shares of Nanogen (NGEN) climbed 16% after Fisher Scientific (FSH) agreed to buy about 5.7 million shares for $2.65 each. The $15 million investment coincides with Fisher's $283 million acquisition of Athena Diagnostics, which was announced Thursday. "Nanogen and Fisher will collaborate to expand the use of Athena's proprietary markets and diagnostic assays," Nanogen said in a statement. Nanogen plans to use proceeds from the stock sale for working capital and other general corporate needs. Shares of were up 41 cents to $2.93, while Fisher shares shed 36 cents to $69.52.

StemCells (STEM - Get Report) shares were roughly flat after the stem cell-focused biotechnology company posted a smaller year-over-year loss. The company reported a loss of $4.3 million, or 7 cents a share, narrowed from $4.9 million, or 8 cents a share, a year earlier. Revenue rose to $43,000 from $38,000. For all of 2005, the company reported a loss of $11.7 million, or 18 cents a share, on revenue of $206,000. The company ended 2005 with $34.5 million in cash and cash equivalents, down from $41.1 million at the end of 2004. Shares were unchanged at $3.69.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
NGEN $0.00 100.00%
MRX $0.00 0.00%
BMRN $120.95 -2.94%
TTP $28.50 -0.04%
STEM $0.99 -2.75%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs